单位 : 兆韩元
致力于成为世界一流的新药研发企业
| Molecule | LR20061 |
|---|---|
| Stage | Preclinical |
| Indication | Atopic Dermatitis |
| Modality | Chemical |
| Target | Undisclosed |
| Molecule | LR19157 |
|---|---|
| Stage | Preclinical |
| Indication | Oncology |
| Modality | Chemical |
| Target | Undisclosed |
| Molecule | CUE-102 |
|---|---|
| Stage | Phase 1 (by Partner) |
| Location summary | USA |
| Indication | Oncology |
| Modality | Biologics |
| Target | WT-1 |
| Partner | Cue Biopharma |
| Molecule | Rilogrotug |
|---|---|
| Stage | Preclinical |
| Location summary | USA |
| Indication | Cachexia |
| Modality | Biologics |
| Target | anti-GDF15 IgG1 mAb |
| Molecule | AV-203 |
|---|---|
| Stage | Phase 1 |
| Location summary | USA |
| Indication | Oncology |
| Modality | Biologics |
| Target | Anti-ERBB3 IgG1 mAb |
| Molecule | LB-LR1109 |
|---|---|
| Stage | Phase 1 |
| Indication | Oncology |
| Modality | Biologics |
| Target | LILRB1 |
| Molecule | LG203003 |
|---|---|
| Stage | Phase 1 |
| Location summary | USA |
| Indication | NASH |
| Modality | NCE |
| Target | DGAT-2 |
| Molecule | Ficlatuzumab |
|---|---|
| Stage | Phase 1b/2 |
| Location summary | USA |
| Indication | Hematology |
| Modality | Biologics |
| Target | Anti-HGF/c-MET IgG1 mAb |
| Molecule | aP vaccine |
|---|---|
| Stage | Phase 2 |
| Indication | aP vaccine |
| Modality | Vaccine |
| Target | aP vaccine |
Diphtheria, Tetanus, Pertussis,Polio, Hib, HebB
| Molecule | Bivamelagon |
|---|---|
| Stage | Phase 2 |
| Location summary | USA |
| Indication | Rare Obesity |
| Modality | NCE |
| Target | MC4R |
| Partner | Rhythm Pharmaceuticals (License-out) |
| Molecule | 6 in 1 Vaccine |
|---|---|
| Stage | Phase 2 |
| Indication | 6 in 1 Vaccine |
| Modality | Vaccine |
| Target | 6 in 1 Vaccine |
Diphtheriae (D), Bordetella pertussis (wP), Clostridium tetani (T), Hepatitis B (HepB) Haemophilus influenzae type b(Hib) Vaccine-Associated Paralytic Poliomyelitis(IPV)
| Molecule | Zectivimod |
|---|---|
| Stage | Phase 2 (by Partner) |
| Location summary | China |
| Indication | Ulcerative colitis Atopic dermatitis |
| Modality | NCE |
| Target | S1P1 |
| Partner | TransThera (License-out) |
License-out, China
| Molecule | Ficlatuzumab |
|---|---|
| Stage | Phase 3 |
| Location summary | Global |
| Indication | Head and neck squamous cell carcinoma |
| Modality | Biologics |
| Target | Anti-HGF/c-MET IgG1 mAb |
| Molecule | Y-solution, MDR |
|---|---|
| Stage | NDA |
| Location summary | Europe |
| Indication | HA filler |
| Modality | HA |
| Target | HA |
| Molecule | Y-solution, China |
|---|---|
| Stage | NDA |
| Location summary | China |
| Indication | HA filler |
| Modality | HA |
| Target | HA |
Eutropin
Hyruan One
Zemiglo / Zemimet SR Tab. / Zemidapa
Eucept
FOTIVDA
当您访问LG化学网站时，信息会以cookie的形式在客户端浏览器中被存储或读取。
该信息可能与您本身、您的偏好或您使用的设备有关，主要用于保持网站的正常运行。这些信息无法直接识别您，但可以为您浏览网站提供更好的体验。
LG化学尊重您的隐私权。您可以通过设置不接受某些类型的cookie，还可以查看详细信息并更改设置。
基本cookie基本
为使用网站的全部功能，基本cookie是必要的。这些cookie用于响应您在浏览网站时的服务需求。
- Amazon Web Service
- Web Application Server
- Application Performance Monitoring
- 是否勾选主页面弹窗的“今日不再显示”
- 是否参与用户调研
分析cookie
该cookie通过收集有关您的网站使用方式来帮助改善网站。例如，匿名收集您使用的设备、访问区域和访问时间等信息。
- Google Analytics (GA4)
- Salesforce Marketing Cloud Account Engagement (MC AE)
